Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.

López-Corral L, Caballero-Velázquez T, López-Godino O, Rosiñol L, Pérez-Vicente S, Fernandez-Avilés F, Krsnik I, Morillo D, Heras I, Morgades M, Rifon JJ, Sampol A, Iniesta F, Ocio EM, Martin J, Rovira M, Cabero M, Castilla-Llorente C, Ribera JM, Torres-Juan M, Moraleda JM, Martinez C, Vázquez A, Gutierrez G, Caballero D, San Miguel JF, Mateos MV, Pérez-Simón JA.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1703-1712. doi: 10.1016/j.bbmt.2019.04.026. Epub 2019 May 3.

PMID:
31054983
2.

Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms.

Carrillo-Cruz E, García-Lozano JR, Márquez-Malaver FJ, Sánchez-Guijo FM, Montero Cuadrado I, Ferra I Coll C, Valcárcel D, López-Godino O, Cuesta M, Parody R, López-Corral L, Alcoceba M, Caballero-Velázquez T, Rodríguez-Gil A, Bejarano-García JA, Ramos TL, Pérez-Simón JA.

Clin Cancer Res. 2019 Aug 1;25(15):4616-4623. doi: 10.1158/1078-0432.CCR-18-3875. Epub 2019 May 1.

PMID:
31043390
3.

Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: "Doublet Technology".

García-Guerrero E, Sánchez-Abarca LI, Domingo E, Ramos TL, Bejarano-García JA, Gonzalez-Campos JA, Caballero-Velázquez T, Pérez-Simón JA.

Front Immunol. 2018 Sep 3;9:1971. doi: 10.3389/fimmu.2018.01971. eCollection 2018.

4.

Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia: A Retrospective Analysis from the Time of Transplant Approval.

Rodríguez-Arbolí E, Márquez-Malaver FJ, Rodríguez-Torres N, Caballero-Velázquez T, Escamilla-Gómez V, Calderón-Cabrera C, Falantes-González JF, Solé-Rodríguez M, García-Ramírez P, Moya-Arnao M, Carreras E, Espigado-Tocino I, Pérez-Simón JA.

Biol Blood Marrow Transplant. 2019 Jan;25(1):183-190. doi: 10.1016/j.bbmt.2018.08.019. Epub 2018 Aug 25.

PMID:
30153492
5.

Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting.

Afram G, Simón JAP, Remberger M, Caballero-Velázquez T, Martino R, Piñana JL, Ringden O, Esquirol A, Lopez-Corral L, Garcia I, López-Godino O, Sierra J, Caballero D, Ljungman P, Vazquez L, Hägglund H.

Med Oncol. 2018 Apr 25;35(6):79. doi: 10.1007/s12032-018-1127-2.

6.

Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy.

Matarraz S, Leoz P, Fernández C, Colado E, Chillón MC, Vidriales MB, González M, Rivera D, Osuna CS, Caballero-Velázquez T, Van Der Velden V, Jongen-Lavrencic M, Gutiérrez O, Bermejo AY, Alonso LG, García MB, De Ramón Sánchez C, García-Donas G, Mateo AG, Recio I, Sánchez-Real J, Mayado A, Gutiérrez ML, Bárcena P, Barrena S, López A, Van Dongen J, Orfao A.

Mod Pathol. 2018 Aug;31(8):1318-1331. doi: 10.1038/s41379-018-0038-2. Epub 2018 Mar 23.

7.

Genotoxicity of tetrahydrofolic acid to hematopoietic stem and progenitor cells.

García-Calderón CB, Bejarano-García JA, Tinoco-Gago I, Castro MJ, Moreno-Gordillo P, Piruat JI, Caballero-Velázquez T, Pérez-Simón JA, Rosado IV.

Cell Death Differ. 2018 Nov;25(11):1967-1979. doi: 10.1038/s41418-018-0089-4. Epub 2018 Mar 6.

PMID:
29511342
8.

MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.

Burillo-Sanz S, Morales-Camacho RM, Caballero-Velázquez T, Carrillo E, Sánchez J, Pérez-López O, Pérez de Soto I, González Campos J, Prats-Martín C, Bernal R, Vargas MT.

Eur J Haematol. 2018 May;100(5):436-443. doi: 10.1111/ejh.13037. Epub 2018 Mar 1.

PMID:
29384595
9.

KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation.

Prats-Martín C, Jiménez-Guerrero P, Morales-Camacho RM, Caballero-Velázquez T, Vargas MT, Pérez O, Montero I, Falantes J, Burillo-Sanz S, Carrillo E, Borrero JJ, Bernal R, Pérez-Simón JA.

Ann Hematol. 2018 Mar;97(3):533-535. doi: 10.1007/s00277-017-3187-3. Epub 2017 Nov 18. No abstract available.

PMID:
29151134
10.

Sensitivity of hematopoietic stem cells to mitochondrial dysfunction by SdhD gene deletion.

Bejarano-García JA, Millán-Uclés Á, Rosado IV, Sánchez-Abarca LI, Caballero-Velázquez T, Durán-Galván MJ, Pérez-Simón JA, Piruat JI.

Cell Death Dis. 2016 Dec 8;7(12):e2516. doi: 10.1038/cddis.2016.411.

11.

Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial.

Caballero-Velázquez T, Montero I, Sánchez-Guijo F, Parody R, Saldaña R, Valcarcel D, López-Godino O, Ferra I Coll C, Cuesta M, Carrillo-Vico A, Sánchez-Abarca LI, López-Corral L, Márquez-Malaver FJ, Pérez-Simón JA; GETH (Grupo Español de Trasplante Hematopoyético).

Clin Cancer Res. 2016 Dec 1;22(23):5673-5681. Epub 2016 Jun 29.

12.

Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo.

Barbado MV, Medrano M, Caballero-Velázquez T, Álvarez-Laderas I, Sánchez-Abarca LI, García-Guerrero E, Martín-Sánchez J, Rosado IV, Piruat JI, Gonzalez-Naranjo P, Campillo NE, Páez JA, Pérez-Simón JA.

Int J Cancer. 2017 Feb 1;140(3):674-685. doi: 10.1002/ijc.30483. Epub 2016 Nov 10.

13.

Caspase-8 inhibition represses initial human monocyte activation in septic shock model.

Oliva-Martin MJ, Sanchez-Abarca LI, Rodhe J, Carrillo-Jimenez A, Vlachos P, Herrera AJ, Garcia-Quintanilla A, Caballero-Velazquez T, Perez-Simon JA, Joseph B, Venero JL.

Oncotarget. 2016 Jun 21;7(25):37456-37470. doi: 10.18632/oncotarget.9648.

14.

Haemophagocytosis by neoplastic cells in aleukaemic variant of mast cell leukaemia.

Morales-Camacho RM, Caballero-Velázquez T, Prats-Martín C, Pérez-López O, Vargas MT, Carrillo-Cruz E.

Br J Haematol. 2016 Aug;174(4):501. doi: 10.1111/bjh.14178. Epub 2016 Jul 19. No abstract available.

PMID:
27431732
15.

Leukaemic blast cannibalism in acute megakaryoblastic leukaemia with myeloid sarcoma.

Morales-Camacho RM, Caballero-Velázquez T, Knight T, García A, Bernal R, Borrero JJ.

Br J Haematol. 2016 May;173(3):336. doi: 10.1111/bjh.14002. Epub 2016 Mar 31. No abstract available.

PMID:
27030205
16.

RUNX1 amplification in AML with myelodysplasia-related changes and ring 21 chromosomes.

Burillo-Sanz S, Vargas MT, Morales-Camacho RM, Caballero-Velázquez T, Sánchez J, García-Lozano JR, Pérez de Soto I, Prats-Martín C, Bernal R, Pérez-Simón JA.

Hematol Oncol. 2017 Dec;35(4):894-899. doi: 10.1002/hon.2287. Epub 2016 Mar 7.

PMID:
26947932
17.

Strong periodic acid-schiff reaction in hypervacuolated blastic plasmacytoid dendritic cell neoplasm.

Prats-Martín C, Morales-Camacho RM, Blum-Domínguez MA, Cabrera-Pérez R, Bernal R, Caballero-Velázquez T, Pérez-Simón JA.

Diagn Cytopathol. 2016 Jan;44(1):39-40. doi: 10.1002/dc.23372. Epub 2015 Oct 15. No abstract available.

PMID:
26467980
18.

NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression.

Burillo-Sanz S, Morales-Camacho RM, Caballero-Velázquez T, Vargas MT, García-Lozano JR, Falantes JF, Prats-Martín C, Bernal R, Pérez-Simón JA.

Int J Lab Hematol. 2016 Feb;38(1):64-71. doi: 10.1111/ijlh.12435. Epub 2015 Sep 29.

PMID:
26418229
19.

Human Bone Marrow Stromal Cells Differentiate Into Corneal Tissue and Prevent Ocular Graft-Versus-Host Disease in Mice.

Sánchez-Abarca LI, Hernández-Galilea E, Lorenzo R, Herrero C, Velasco A, Carrancio S, Caballero-Velázquez T, Rodríguez-Barbosa JI, Parrilla M, Del Cañizo C, San Miguel J, Aijón J, Pérez-Simón JA.

Cell Transplant. 2015;24(12):2423-33. doi: 10.3727/096368915X687480. Epub 2015 Feb 18.

PMID:
25695936
20.

Myelomatous plasma cells display an aberrant gene expression pattern similar to that observed in normal memory B cells.

Báez A, Piruat JI, Caballero-Velázquez T, Sánchez-Abarca LI, Álvarez-Laderas I, Barbado MV, García-Guerrero E, Millán-Uclés Á, Martín-Sánchez J, Medrano M, Pérez-Simón JA.

Am J Cancer Res. 2014 Dec 15;5(1):386-95. eCollection 2015.

21.

Multiple pseudo-Chediak-Higashi inclusions associated with MYC deletion in a patient with acute myeloid leukemia.

Vargas MT, Escamilla V, Morales-Camacho RM, Prats C, Caballero-Velázquez T, Bernal R, Pérez Simón JA.

Acta Haematol. 2015;133(4):321-3. doi: 10.1159/000366095. Epub 2014 Dec 2. No abstract available.

PMID:
25471154
22.

GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT.

Parody R, Lopez-Corral L, Godino OL, Cadenas IG, Martinez AP, Vazquez L, Martino R, Martinez C, Solano C, Barba P, Valcarcel D, Caballero-Velazquez T, Marquez-Malaver FJ, Sierra J, Caballero D, Perez-Simón JA.

Bone Marrow Transplant. 2015 Jan;50(1):121-6. doi: 10.1038/bmt.2014.220. Epub 2014 Oct 13.

PMID:
25310306
23.

The CD27+ memory B cells display changes in the gene expression pattern in elderly individuals.

Báez A, Alvarez-Laderas I, Piruat JI, Caballero-Velázquez T, Barbado MV, Millán-Uclés A, Medrano M, García-Guerrero E, Sánchez-Abarca L, Pérez-Simón JA.

Immunology. 2014 Sep 6. doi: 10.1111/imm.12381. [Epub ahead of print]

24.

Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.

Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, Olavarría E, Andreu E, Prósper F, Díez-Campelo M, Regidor C, Villaron E, López-Corral L, Caballero D, Cañizo MC, Pérez-Simon JA.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1580-5. doi: 10.1016/j.bbmt.2014.06.015. Epub 2014 Jun 19.

25.

Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma.

Paiva B, Chandia M, Vidriales MB, Colado E, Caballero-Velázquez T, Escalante F, Garcia de Coca A, Montes MC, Garcia-Sanz R, Ocio EM, Mateos MV, San Miguel JF.

Blood. 2014 Aug 21;124(8):1300-3. doi: 10.1182/blood-2014-04-567909. Epub 2014 May 29.

26.

Differential cytogenetic profile in advanced chronic myeloid leukemia with sequential lymphoblastic and myeloblastic blast crisis.

Calderón-Cabrera C, Montero I, Morales RM, Sánchez J, Carrillo E, Caballero-Velázquez T, Prats C, Bernal R, De Blas JM, Pérez-Simón JA.

Leuk Res Rep. 2013 Sep 21;2(2):79-81. doi: 10.1016/j.lrr.2013.08.001. eCollection 2013.

27.

Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.

Caballero-Velázquez T, López-Corral L, Encinas C, Castilla-Llorente C, Martino R, Rosiñol L, Sampol A, Caballero D, Serrano D, Heras I, San Miguel J, Pérez-Simón JA.

Br J Haematol. 2013 Aug;162(4):474-82. doi: 10.1111/bjh.12410. Epub 2013 Jun 15.

PMID:
23772672
28.

Uptake and delivery of antigens by mesenchymal stromal cells.

Sánchez-Abarca LI, Alvarez-Laderas I, Díez Campelo M, Caballero-Velázquez T, Herrero C, Muntión S, Calderón C, García-Guerrero E, Sánchez-Guijo F, Del Cañizo C, San Miguel J, Pérez-Simón JA.

Cytotherapy. 2013 Jun;15(6):673-8. doi: 10.1016/j.jcyt.2013.01.216. Epub 2013 Mar 21.

PMID:
23522868
29.

The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.

Caballero-Velázquez T, Sánchez-Abarca LI, Gutierrez-Cosio S, Blanco B, Calderon C, Herrero C, Carrancio S, Serrano C, del Cañizo C, San Miguel JF, Pérez-Simón JA.

Haematologica. 2012 Sep;97(9):1329-37. doi: 10.3324/haematol.2011.058677. Epub 2012 Apr 24.

30.

Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment.

Gutierrez-Cosío S, de la Rica L, Ballestar E, Santamaría C, Sánchez-Abarca LI, Caballero-Velazquez T, Blanco B, Calderón C, Herrero-Sánchez C, Carrancio S, Ciudad L, Cañizo C, San Miguel JF, Pérez-Simón JA.

Leuk Res. 2012 Jul;36(7):895-9. doi: 10.1016/j.leukres.2012.02.030. Epub 2012 Apr 13.

PMID:
22503131
31.

Evaluation of prognostic factors among patients with chronic graft-versus-host disease.

Pérez-Simón JA, Afram G, Martino R, Piñana JL, Caballero-Velazquez T, Ringden O, Valcarcel D, Caballero D, Remberger M, de Paz Y, Sierra J, Miguel JS, Hagglund H.

Haematologica. 2012 Aug;97(8):1187-95. doi: 10.3324/haematol.2011.055244. Epub 2012 Feb 27.

32.

Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens.

Blanco B, Sánchez-Abarca LI, Caballero-Velázquez T, Santamaría C, Inogés S, Pérez-Simón JA.

Leuk Res. 2011 Oct;35(10):1412-5. doi: 10.1016/j.leukres.2011.05.018. Epub 2011 Jun 11.

PMID:
21658766
33.

[Classification of chronic graft-versus-host disease].

Caballero Velázquez T, Pérez Simón JA.

Methods Find Exp Clin Pharmacol. 2010 Dec;32 Suppl A:65-8. Spanish.

PMID:
21381291
34.

Effect of vitamin D treatment in chronic GVHD.

Silva F, Pérez-Simón JA, Caballero-Velazquez T, Sánchez-Guijo FM, Villanueva-Gomez F, Vazquez L, del Cañizo C, Caballero D, San Miguel J.

Bone Marrow Transplant. 2011 Oct;46(10):1395-7. doi: 10.1038/bmt.2010.317. Epub 2011 Jan 17. No abstract available.

35.

Helicobacter pylori infection and graft-versus-host disease.

Velasco Guardado A, López-Corral L, Pérez-Simón JA, Caballero-Velázquez T, Flores Corral T, Caballero Barrigón D, Rodríguez Pérez A.

Biol Blood Marrow Transplant. 2011 May;17(5):765-9. doi: 10.1016/j.bbmt.2010.11.014. Epub 2010 Nov 18.

36.

Limbus damage in ocular graft-versus-host disease.

Pérez RL, Pérez-Simón JA, Caballero-Velazquez T, Flores T, Carrancio S, Herrero C, Blanco B, Gutierrez-Cosio S, Cañete-Campos C, Cruz González F, San-Miguel JF, Hernández-Galilea E, Sánchez-Abarca I.

Biol Blood Marrow Transplant. 2011 Feb;17(2):270-3. doi: 10.1016/j.bbmt.2010.08.008. Epub 2010 Aug 26.

37.

Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant.

Silva F, Pérez-Simón JA, Caballero Velazquez T, Encinas C, Sánchez-Guijo FM, Díez-Campelo M, Colado E, Martín J, Villanueva-Gomez F, Vazquez L, Del Cañizo C, Caballero D, San Miguel J.

Am J Hematol. 2010 Apr;85(4):290-3. doi: 10.1002/ajh.21613. No abstract available.

38.

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting.

Sánchez-Abarca LI, Gutierrez-Cosio S, Santamaría C, Caballero-Velazquez T, Blanco B, Herrero-Sánchez C, García JL, Carrancio S, Hernández-Campo P, González FJ, Flores T, Ciudad L, Ballestar E, Del Cañizo C, San Miguel JF, Pérez-Simon JA.

Blood. 2010 Jan 7;115(1):107-21. doi: 10.1182/blood-2009-03-210393. Epub 2009 Nov 3.

39.

Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease.

Villanueva FN, Pérez-Simón JA, Silva FF, Caballero-Velázquez TT, Sánchez-Guijo FF, Cañizo CC, Vázquez LL, Caballero DD, San Miguel JF.

Biol Blood Marrow Transplant. 2009 Oct;15(10):1331-6. doi: 10.1016/j.bbmt.2009.05.018. Epub 2009 Jul 22.

40.

Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.

Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Caballero-Velazquez T, Gutierrez-Cossío S, Hernández-Campo P, Díez-Campelo M, Herrero-Sanchez C, Rodriguez-Serrano C, Santamaría C, Sánchez-Guijo FM, Del Cañizo C, San Miguel JF.

Haematologica. 2009 Jul;94(7):975-83. doi: 10.3324/haematol.2008.005017. Epub 2009 Jun 8.

Supplemental Content

Loading ...
Support Center